Hookipa Pharma (HOOK) Competitors

Jaguar Health (NASDAQ:JAGX) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Does the media refer more to JAGX or HOOK?

In the previous week, Jaguar Health had 5 more articles in the media than Hookipa Pharma. MarketBeat recorded 8 mentions for Jaguar Health and 3 mentions for Hookipa Pharma. Jaguar Health's average media sentiment score of 0.59 beat Hookipa Pharma's score of 0.14 indicating that Hookipa Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jaguar Health	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hookipa Pharma	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, JAGX or HOOK?

Jaguar Health has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Do institutionals & insiders believe in JAGX or HOOK?

12.0% of Jaguar Health shares are held by institutional investors. Comparatively, 63.9% of Hookipa Pharma shares are held by institutional investors. 0.2% of Jaguar Health shares are held by company insiders. Comparatively, 5.8% of Hookipa Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community prefer JAGX or HOOK?

Jaguar Health received 1750 more outperform votes than Hookipa Pharma when rated by MarketBeat users. Likewise, 89.08% of users gave Jaguar Health an outperform vote while only 69.11% of users gave Hookipa Pharma an outperform vote.

Company	Underperform	Outperform
Jaguar Health	Outperform Votes 1835 89.08%	Underperform Votes 225 10.92%
Hookipa Pharma	Outperform Votes 85 69.11%	Underperform Votes 38 30.89%

Which has stronger earnings & valuation, JAGX or HOOK?

Jaguar Health has higher earnings, but lower revenue than Hookipa Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Health	$9.76M	7.32	-$41.30M	N/A	N/A
Hookipa Pharma	$20.13M	4.01	-$81.58M	-$0.50	-1.63

Is JAGX or HOOK more profitable?

Hookipa Pharma has a net margin of -88.73% compared to Hookipa Pharma's net margin of -377.95%. Jaguar Health's return on equity of -33.33% beat Hookipa Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jaguar Health	-377.95%	-642.15%	-75.53%
Hookipa Pharma	-88.73%	-33.33%	-20.22%

Do analysts prefer JAGX or HOOK?

Hookipa Pharma has a consensus price target of $4.67, suggesting a potential upside of 472.32%. Given Jaguar Health's higher possible upside, analysts plainly believe Hookipa Pharma is more favorable than Jaguar Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Hookipa Pharma	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Hookipa Pharma beats Jaguar Health on 10 of the 15 factors compared between the two stocks.